Patents by Inventor William Wachsman

William Wachsman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell-type-specific patterns of gene expression
    Patent number: 8781750
    Abstract: Among the methods, compositions, combinations and kits provided herein are those for determining gene expression levels in one or more cell types in heterogeneous cell samples, for identifying genes differentially expressed in different cell types, and for detecting a cell type in a sample from a subject. Also provided herein are methods, compositions, combinations and kits for determining gene expression levels in cells corresponding to phenotypes, and for identifying a phenotype of a subject by detecting differentially expressed genes.
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: July 15, 2014
    Assignees: The Regents of the University of California, Sidney Kimmel Cancer Center, Ludwig Institute for Cancer Research
    Inventors: William Wachsman, Daniel Mercola, Michael McClelland, Jessica Wang-Rodriguez, David Tarin, Charles C. Berry, Karen Arden, Linda Wasserman, Steven Goodison, Igor Klacansky, Elizabeth Duff Stuart
  • Cell-type-specific patterns of gene expression
    Publication number: 20060292572
    Abstract: Among the methods, compositions, combinations and kits provided herein are those for determining gene expression levels in one or more cell types in heterogeneous cell samples, for identifying genes differentially expressed in different cell types, and for detecting a cell type in a sample from a subject. Also provided herein are methods, compositions, combinations and kits for determining gene expression levels in cells corresponding to phenotypes, and for identifying a phenotype of a subject by detecting differentially expressed genes.
    Type: Application
    Filed: January 10, 2005
    Publication date: December 28, 2006
    Inventors: Robert Stuart, Elizabeth Stuart, William Wachsman, Daniel Mercola, Michael McClelland, Jessica Wang-Rodriguez, David Tarin, Charles Berry, Karen Arden, Linda Wasserman, Steven Goodison, Igor Klacansky
  • Human T-cell leukemia virus transcription modulators and screening assays
    Patent number: 5693759
    Abstract: The invention provides methods and compositions relating to the Tax-response Complex-1 (TRC-1) a transcription complex associated with disease, particularly HTLV infection. TRC-1 is composed of novel forms of JunB and a member of a novel protein family called small nuclear factors or SNFs. The expression of these compounds are shown to correlate with cell lineage, activation and infection. SNFs and T-cell specific forms of JunB, find particular use in screening assays for agents or lead compounds for agents useful in the diagnosis, prognosis or treatment of disease, particularly HTLV infection. Nucleic acids encoding SNFs, and SNF-specific binding agents find use in diagnosis and as commercial reagents for the biopharmaceutical industry.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: December 2, 1997
    Assignee: Regents of The University of California
    Inventors: William Wachsman, Tracy Martin, Wolfgang Klump
  • Human T-cell leukemia virus transcription modulators and screening assays
    Patent number: 5616475
    Abstract: The invention provides methods and compositions relating to the Tax-response Complex-1 (TRC-1) a transcription complex associated with disease, particularly HTLV infection. TRC-1 is composed of novel forms of JunB and a member of a novel protein family called small nuclear factors or SNFs. The expression of these compounds are shown to correlate with cell lineage, activation and infection. SNFs and T-cell specific forms of JunB, find particular use in screening assays for agents or lead compounds for agents useful in the diagnosis, prognosis or treatment of disease, particularly HTLV infection. Nucleic acids encoding SNFs, and SNF-specific binding agents find use in diagnosis and as commercial reagents for the biopharmaceutical industry.
    Type: Grant
    Filed: February 3, 1995
    Date of Patent: April 1, 1997
    Assignee: The Regents of the University of California
    Inventors: William Wachsman, Tracy Martin, Wolfgang Klump